Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
1000 participants
OBSERVATIONAL
2017-01-31
2019-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The investigators plan on doing this analysis longitudinally across gestation in multiple trimesters to analyze the ability to predict maternal morbid conditions prior to the current clinically-based criteria as a novel marker to aid in routine prenatal care, as compared to the traditional weight measurement currently being done.
Both increased maternal prepregnancy weight (body mass index) and increased maternal gestational weight gain have been associated with increased risks of multiple obstetrical complications (both maternal and fetal). The investigators seek to compare the current standard with BIA in its ability to predict maternal/fetal adverse outcomes such as gestational diabetes, preeclampsia, and cesarean delivery.
PRIOR RESEARCH
There are a few studies in pregnant patients correlating BIA and pregnancy outcomes:
1. Sween et al performed BIA on 370 women and found that body fat composition correlated with the development of preeclampsia.
2. Gomes de Silva et al performed BIA in 65 women with preeclampsia and 51 controls and found that BIA results differed between the two groups.
3. Marshall et al performed BIA on 41 pregnant women in the third trimester as part of a multimodal analysis of body composition
4. Xu et al correlated BIA with the onset of gestational diabetes
PROTOCOL
* Patients in this MFM practice will be approached at the time of their initial pregnancy visit and asked to participate.
* If they agree and sign informed consent, the following will occur:
* The participant's name will be placed on a list of participants
* The participant will have an InBody analysis performed by one of the office nurses or medical assistants. The results will not be shared with the participant nor the treating physicians. Rather, the results will be filed until after the participant delivers.
* Participants will have the InBody analysis performed in each trimester at the time of scheduled office visits as well as at the post-partum visit, which is routinely scheduled at approximately 6 weeks after delivery. Those results will also not be shared with the participants or physicians.
* After the postpartum visit, the data from the InBody analysis will be entered into a de-identified database, along with the participant's baseline characteristics, pregnancy events, and delivery outcomes, all of which are already in the participant's office chart. No personal identifiers will be required for the database. The data will be used to correlate InBody results with pregnancy outcomes.
* The only identifier will be the actual list of participants, which is required to plan for who needs InBody analysis during their prenatal visit.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Pregnant women
all consecutive pregnant women presenting for prenatal care
BIA measurement
observation only
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
BIA measurement
observation only
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
60 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Maternal Fetal Medicine Associates
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Nathan Fox
Physician
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Maternal Fetal Medicine Associates
New York, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Nathan Fox, MD
Role: primary
Andrei Rebarber, MD
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1
Identifier Type: -
Identifier Source: org_study_id